Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.
Exposure to maternal overnutrition increases the expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) in adipose tissue before birth, and it has been proposed that the precocial activation of PPARgamma target genes may lead to increased fat deposition in postnatal life. In this study, we determined the effect of intrafetal administration of a PPARgamma agonist, rosiglitazone, on PPARgamma target gene expression in fetal adipose tissue as well indirect actions of rosiglitazone on fetal liver and skeletal muscle. Osmotic pumps containing rosiglitazone (n = 7) or vehicle (15% ethanol, n = 7) were implanted into fetuses at 123-126 d gestation (term = 150 +/- 3 d gestation). At 137-141 d gestation, tissues were collected and mRNA expression of PPARgamma, lipoprotein lipase (LPL), adiponectin, and glycerol-3-phosphate dehydrogenase (G3PDH) in adipose tissue, PPARalpha and PPARgamma-coactivator 1alpha (PGC1alpha) in liver and muscle and phosphoenolpyruvate carboxykinase (PEPCK) in liver determined by quantitative real-time RT-PCR. Plasma insulin concentrations were lower in rosiglitazone-treated fetuses (P < 0.02). Rosiglitazone treatment resulted in increased expression of LPL and adiponectin mRNA (P < 0.01) in fetal adipose tissue. The expression of PPARalpha mRNA in liver (P < 0.05) and PGC1alpha mRNA (P < 0.02) in skeletal muscle were also increased by rosiglitazone treatment. Rosiglitazone treatment increased expression of PPARgamma target genes within fetal adipose tissue and also had direct or indirect actions on the fetal liver and muscle. The effects of activating PPARgamma in fetal adipose tissue mimic those induced by prenatal overnutrition, and it is therefore possible that activation of PPARgamma may be the initiating mechanism in the pathway from prenatal overnutrition to postnatal obesity.
Muhlhausler
B S
BS
Sansom Research Institute, University of South Australia, Adelaide 5000, Australia. Beverly.Muhlhausler@unisa.edu.au.
Morrison
J L
JL
McMillen
I C
IC
D052242:Adiponectin / Q000096:biosynthesis; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D005260:Female; D005333:Fetus / Q000187:drug effects; D050536:Glycerol-3-Phosphate Dehydrogenase (NAD+) / Q000096:biosynthesis; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000096:biosynthesis; D008071:Lipoprotein Lipase / Q000096:biosynthesis; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D039382:Maternal Nutritional Physiological Phenomena; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D047493:PPAR alpha / Q000096:biosynthesis; D047495:PPAR gamma / Q000096:biosynthesis / Q000235:genetics*; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000096:biosynthesis; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D012333:RNA, Messenger / Q000378:metabolism; D000077154:Rosiglitazone; D012756:Sheep; D045162:Thiazolidinediones / Q000494:pharmacology*; D015534:Trans-Activators / Q000096:biosynthesis
D052242:Adiponectin; D007328:Insulin; D020738:Leptin; D047493:PPAR alpha; D047495:PPAR gamma; D012333:RNA, Messenger; D045162:Thiazolidinediones; D015534:Trans-Activators; D000077154:Rosiglitazone; D050536:Glycerol-3-Phosphate Dehydrogenase (NAD+); D008071:Lipoprotein Lipase; D010729:Phosphoenolpyruvate Carboxykinase (GTP)